Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors

NEXT STORY
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
PREV STORY
Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

author_avatar
NASDAQ Market News

Roche receives CE Mark for its Accu-Chek SugarView app

author_avatar
NASDAQ Market News

Celsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer – The Focus of Hepatic Oncology Peer-Reviewed Article

Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency ...

author_avatar
NASDAQ Market News